Marksans Pharma (NSE:MARKSANS) EV-to-EBIT : 16.34 (As of May. 26, 2024)

Marksans Pharma EV-to-EBIT Chart

Marksans Pharma Annual Data
	Trend	Mar14	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23
EV-to-EBIT		Get a 7-Day Free Trial					9.97	3.20	6.18	6.51	7.49

Marksans Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															7.94	7.49	11.37	10.98	16.63

Competitive Comparison of Marksans Pharma's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Marksans Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marksans Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's EV-to-EBIT falls into.

Marksans Pharma EV-to-EBIT Calculation

Marksans Pharma's EV-to-EBIT for today is calculated as:

Marksans Pharma's current Enterprise Value is ₹70,729 Mil.
Marksans Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,328 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marksans Pharma  (NSE:MARKSANS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Marksans Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Marksans Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was ₹71,962 Mil.
Marksans Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,328 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marksans Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Marksans Pharma (NSE:MARKSANS) Business Description